drugset
drugset / Trial / NCT01004016

A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

NCT01004016 ↗

Phase 2 Completed 20 enrolled Kissei Pharmaceutical Co., Ltd.
RandomizedCrossoverDouble-blindTreatment

Summary

To evaluate the efficacy and safety of KPS-0373 in patients with SCD.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject rovatirelin Small molecule — —

Indications

cerebellar degeneration